Can AI scribes give nurses their time back?
NCT ID NCT07742618
First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time
Summary
This trial tests whether an AI-assisted documentation tool (an 'AI scribe') can help nurses by reducing time spent on record-keeping. About 400 nurses from child and student health services in a Finnish region will adopt the tool at different times, allowing comparison between early and later users. The study looks at effects on working hours, completion of health check-ups, and nurses' job satisfaction and workload.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AI clinical documentation tool (AI scribe)
- What this could lead to
- If effective, AI-assisted documentation could reduce nurses' administrative burden, improve job satisfaction, and allow more time for patient care.
- What could go wrong
- The trial is relatively small and focuses on specific health services, so results may not apply broadly. AI tools can also introduce errors or workflow disruptions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EFFECTIVENESS OF AI-ASSISTED CLINICAL DOCUMENTATION TOOL are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Turku
Turku, Finland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test